What It Takes to Make the Pathway: Clinical and Operational Criteria for Adding New Combinations in RRFL

This episode, titled 'What It Takes to Make the Pathway: Clinical and Operational Criteria for Adding New Combinations in RRFL,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the following critical question:

1. What clinical and operational criteria does your institution use to evaluate whether the incremental benefit of a new combination justifies its addition to existing pathways?

Ryan Haumschild outlined the three-part framework his institution uses to evaluate new combination regimens for formulary and pathway inclusion, anchored first in efficacy, emphasizing that a novel mechanism of action only earns its place on a pathway when it delivers meaningfully better outcomes than existing standards of care, not merely a different approach to the same result. He further discussed the importance of a manageable safety profile as the second pillar of evaluation, noting that while not every patient will be a candidate for more intensive combinations, pathways should be designed to prioritize the best available therapy for those who can tolerate it. Ryan Haumschild also addressed cost-effectiveness as the third and equally critical consideration, arguing that the availability of generic lenalidomide and biosimilar rituximab meaningfully offsets the incremental cost of adding tafasitamab, and that when a triplet regimen produces a hazard ratio of approximately 0.43 and extends median progression-free survival from roughly 14 to 22 months, the investment is justified: preventing early disease progression ultimately reduces the escalating total cost of care that accompanies each successive treatment failure.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Epcoritamab in RRFL: Efficacy Data, Administration Considerations, and the Pharmacist's Operational Role,' Ryan Haumschild will continue his discussion on follicular lymphoma and highlight the latest efficacy and safety data from the EPCORE FL-1 trial, the key operational and clinical differentiators of epcoritamab as a bispecific T-cell engager, and the infrastructure considerations that pharmacists must address to successfully implement this therapy across care settings.